Table 2.
Clinical and biochemical characteristics and treatment outcomes of patients with PP from PUMCH.
| Patient ID | Pretreatment | Tx for PP | Tx duration (y) | Posttreatment | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BA/CA | PAHZ-score | GV (cm/y)Z-score | LH (IU/L) | Peak LH(IU/L) | FSH (IU/L) | E2 (pg/ml) | T(ng/ml) | Mean testicular or ovarian volumn(mm3) | BA/CA | PAHZ-score | Predicted Ht (cm) | Predicted HtZ-score | Final HtZ-score | GV (cm/y)Z-score | LH (IU/L) | FSH(IU/L) | E2(pg/ml) | T (ng/ml) | Mean testicular or ovarian volumn(mm3) | |||
| 1 | 1.44 | +4.9 | +8.99 | 0.21 | 2.2 | 2.10 | 10.2 | <0.1 | 1.6 | None | 1.0 | 157.5 | −0.5 | +3.3 | −2.10 | |||||||
| 2 | 1.43 | −0.2 | NA | 2.60 | 25.6 | 8.40 | 21.1 | 1.39 | 4.2 | GnRHa | 0.25 | NA | NA | 171.0 | −0.2 | −0.3 | NA | 0.40 | 0.46 | 26.30 | 0.21 | NA |
| 3 | 1.39 | +2.1 | +12.40 | <0.2 | 1.15 | 0.25 | 216.0 | <0.1 | 1.8 | None | 1.02 | +2.6 | 161.5 | 0.1 | −0.6 | <0.2 | 0.25 | 11.05 | <0.1 | 2.6 | ||
| 5 | 1.53 | +0.41 | +13.38 | <0.2 | 0.98 | 0.78 | 165.0 | 0.31 | 7.5 | Tamoxifen 5 mg bid | 5.25 | 1.24 | +2.1 | 162.5 | 0.3 | +1.91 | <0.2 | 0.31 | 33.00 | 0.22 | 1.7 | |
| 6 | 1.98 | −0.3 | +11.72 | 1.14 | 1.20 | 0.78 | 21.0 | 1.65 | 3.3 | Letrozole 2.5 mg qod Medroxyprogesterone 4 mg bid |
2.25 | 1.53 | +2.1 | 174.5 | 0.3 | −0.94 | <0.2 | 0.32 | <5 | 1.12 | 4.4 | |
| 7 | 1.40 | +0.2 | +10.97 | <0.2 | 3.76 | 0.11 | 57.73 | <0.1 | 2.3 | Letrozole 1.25 mg qd | 0.5 | 1.27 | +0.9 | 163 | 0.4 | 2.35 | 0.26 | 3.36 | 11.06 | <0.1 | 1.3 | |
BA/CA, bone age over chronological age; PAH, predicted adult height; GV, growth velocity; LH, luteinizing hormone; FSH, follicle-stimulating hormone; Tx, treatment; E2, estradiol; T, testosterone; Y, year; Ht, height; NA, not available. Peak LH was LH level after GnRH stimulation test. The posttreatment sex hormones and average ovarian measurements for patient 1 are not listed because she was sexually mature at the last follow-up at age 17.